 Since then, multiple researchers have been attempting to expand the therapeutic applications of RNAi, specifically looking to target genes that cause various types of cancer.By 2006, the first applications to reach clinical trials were in the treatment of macular degeneration and respiratory syncytial virus.Four years later the first-in-human Phase I clinical trial was started, using a nanoparticle delivery system to target solid tumors.